Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant-Reference-Cited by-同舟云学术

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Published:2021-05-20 Issue:20 Volume:384 Page:1899-1909
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Shinde Vivek¹,Bhikha Sutika¹,Hoosain Zaheer¹,Archary Moherndran¹,Bhorat Qasim¹,Fairlie Lee¹,Lalloo Umesh¹,Masilela Mduduzi S.L.¹,Moodley Dhayendre¹,Hanley Sherika¹,Fouche Leon¹,Louw Cheryl¹,Tameris Michele¹,Singh Nishanta¹,Goga Ameena¹,Dheda Keertan¹,Grobbelaar Coert¹,Kruger Gertruida¹,Carrim-Ganey Nazira¹,Baillie Vicky¹,de Oliveira Tulio¹,Lombard Koen Anthonet¹,Lombaard Johan J.¹,Mngqibisa Rosie¹,Bhorat As’ad E.¹,Benadé Gabriella¹,Lalloo Natasha¹,Pitsi Annah¹,Vollgraaff Pieter-Louis¹,Luabeya Angelique¹,Esmail Aliasgar¹,Petrick Friedrich G.¹,Oommen-Jose Aylin¹,Foulkes Sharne¹,Ahmed Khatija¹,Thombrayil Asha¹,Fries Lou¹,Cloney-Clark Shane¹,Zhu Mingzhu¹,Bennett Chijioke¹,Albert Gary¹,Faust Emmanuel¹,Plested Joyce S.¹,Robertson Andreana¹,Neal Susan¹,Cho Iksung¹,Glenn Greg M.¹,Dubovsky Filip¹,Madhi Shabir A.¹

Affiliation:

1. From Novavax, Gaithersburg, MD (V.S., L. Fries, S.C.-C., M.Z., C.B., G.A., E.F., J.S.P., A.R., S.N., I.C., G.M.G., F.D.); and the South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences (S.B., V.B., A.L.K., A.O.-J., A.T., S.A.M.), Wits Reproductive Health and HIV Institute (L. Fairlie, G.B.), University of the Witwatersrand, and Soweto Clinical Trials Centre (Q.B., A.E.B.), Johannesburg, Josha Research Centre, Bloemfontein (Z.H., J.J.L....

Funder

Novavax

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2103055

Cited by 510 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and limitations of repurposed drugs and vaccines for COVID-19;Journal of Medicine, Surgery, and Public Health;2024-04

2. Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19;Microbial Cell Factories;2024-02-06

3. One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial;Vaccine;2024-02

4. Protein subunit vaccines: Promising frontiers against COVID-19;Journal of Controlled Release;2024-02

5. COVID-19 breakthrough infections among people living with and without HIV: A statewide cohort analysis;International Journal of Infectious Diseases;2024-02